Two other inhibitors of AKT activation, UCN-01, a staurosproine derivative that blocks PDK1 mediated phosphorylation of AKT [92] and Perifosine an orally available alkylphospholipid that prevents recruitment of AKT to membrane for activation [93], were evaluated in combination in a phase I trial in AML and MDS patients. Here, AKT1 is linked to acute myeloid leukemia.